UNSPSC 41181515: Ceruloplasmin immunological test system

In this classification, a Ceruloplasmin immunological test system is a device that consists of the reagents used to identify by immunochemical techniques Ceruloplasmin. US FDA regulates Ceruloplasmin immunological test system under 21 CFR 866.5210 and under FDA product code DDB.

UNSPSC 41181515, Ceruloplasmin immunological test system, is a Commodity code that shows no recent state and local procurement activity aligned with its nominal scope. The recent opportunities posted under this code span precision optical measurement systems, airfield photometric testing, drug discovery software, electrical meter test equipment, high-voltage diagnostic modules, water quality analysis instruments, laboratory equipment repair and maintenance, atmospheric hazard sensors, material testing systems, and specialized instrumentation for utilities and educational institutions—none of which involve ceruloplasmin immunological testing or clinical laboratory immunoassay systems. The mismatch between the code name and the work actually being solicited suggests either systematic miscoding in the source data or that this code does not currently reflect active state and local procurement demand for ceruloplasmin test systems.

The issuing bodies represented in the recent postings include municipal electric utilities (City of Ocala, Kissimmee Utility Authority), transit and airport authorities (Lee County Port Authority), colleges and universities (Valencia College, Jackson State University, Texas State University, Texas A&M University System), county and city departments (Collier County, City of Tampa, City of Phoenix), state health agencies (Texas Department of State Health Services), state transportation (Colorado State Patrol), county corrections (Marion County, Oregon), and a municipal water utility (Lubbock Power & Light). Florida, Texas, Colorado, Oregon, and Arizona appear most frequently in the recent postings. If pursuit under this code depends on immunological or clinical diagnostic testing rather than the equipment categories shown, the available evidence does not support current market demand.